Company Encyclopedia
View More
name
ZHONGZHIPHARM
03737.HK
Zhongzhi Pharmaceutical Holdings Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People’s Republic of China. The company operates through Pharmaceutical Manufacturing and Operation of Chain Pharmacies segments. It also provides Chinese patent medicines and decoction pieces under the Zeus, Liumian, and Caojinghua brand names. In addition, the company manufactures and sells food and Chinese herbs; offers detection and testing services; and manages properties.
1.450 T
03737.HKMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking33/48
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE1.88%C
    • Profit Margin1.02%C
    • Gross Margin54.80%B
  • Growth ScoreD
    • Revenue YoY-1.67%D
    • Net Profit YoY-81.51%E
    • Total Assets YoY-4.30%D
    • Net Assets YoY-0.04%C
  • Cash ScoreB
    • Cash Flow Margin9763.25%A
    • OCF YoY-1.67%D
  • Operating ScoreA
    • Turnover1.05A
  • Debt ScoreC
    • Gearing Ratio40.81%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    ZHONGZHIPHARM: Jiang Lixia has been appointed as a member of the Nomination Committee

    According to the Zhitong Finance APP, ZHONGZHIPHARM announced that Mr. Lai Zhitian will no longer serve as a member of the company's nomination committee on August 26, 2025. Non-executive director Ms. Jiang Lixia has been appointed as a member of the nomination committee, effective from August 26, 2025

    Zhitong·
    HK
    03737
    0.00%
    Zhitong·
    HK
    03737
    0.00%

    ZHONGZHIPHARM released its interim results, with profit attributable to shareholders of 8.783 million yuan, a year-on-year decrease of 89.5%

    According to the Zhitong Finance APP, ZHONGZHIPHARM released its performance report for the six months ending June 30, 2025, with revenue of 880 million yuan (RMB, the same below), a year-on-year decrease of 19.1%; profit attributable to the parent company owners was 8.783 million yuan, a year-on-year decrease of 89.5%; basic earnings per share were 0.010 yuan

    Zhitong·
    HK
    03737
    0.00%
    Zhitong·
    HK
    03737
    0.00%

    ZHONGZHIPHARM issued a profit warning, expecting a year-on-year decline of approximately 90% in mid-term net profit

    According to the Zhitong Finance APP, ZHONGZHIPHARM announced that it expects its net profit for the six months ending June 30, 2025, to decline by approximately 90% compared to the same period last year. In 2025, due to industry policy adjustments leading to a short-term decline in sales revenue, profits will be affected to some extent. The group will maintain its market investment efforts and actively explore new business growth points

    Zhitong·
    HK
    03737
    0.00%
    Zhitong·
    HK
    03737
    0.00%

    ZHONGZHIPHARM: Zhu Shangheng has been appointed as an independent non-executive director

    According to the Zhitong Finance APP, ZHONGZHIPHARM announced that starting from April 10, 2025: Zhu Shangheng has been appointed as the company's independent non-executive director, chairman of the remuneration committee and nomination committee, and a member of the audit committee. Huang Jinhua has resigned as the company's independent non-executive director, chairman of the remuneration committee and nomination committee, and a member of the audit committee

    Zhitong·
    HK
    03737
    0.00%
    Zhitong·
    HK
    03737
    0.00%

    ZHONGZHIPHARM released its annual performance, with a profit attributable to shareholders of 95.212 million yuan, a year-on-year decrease of 41.51%

    ZHONGZHIPHARM released its annual results for the year ending December 31, 2024, with revenue of 2.215 billion yuan, a year-on-year increase of 8.05%; profit attributable to shareholders of 95.212 million yuan, a year-on-year decrease of 41.51%; basic earnings per share of 0.11 yuan, and a proposed final dividend of 5 Hong Kong cents per share. Pharmaceutical revenue grew by approximately 14.7%, accounting for 73.3% of total revenue

    Zhitong·
    HK
    03737
    0.00%
    Zhitong·
    HK
    03737
    0.00%
    © 2025 Longbridge｜Disclaimer